These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26110878)

  • 1. Effects of Tumour Necrosis Factor Antagonists on Insulin Sensitivity/Resistance in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Burska AN; Sakthiswary R; Sattar N
    PLoS One; 2015; 10(6):e0128889. PubMed ID: 26110878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin-Sensiting Effects of Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Leporini C; Russo E; D Angelo S; Arturi F; Tripepi G; Peluso R; Grembiale RD; Olivieri I; De Sarro G; Ursini F
    Rev Recent Clin Trials; 2018; 13(3):184-191. PubMed ID: 29542420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis.
    Stavropoulos-Kalinoglou A; Metsios GS; Panoulas VF; Nightingale P; Koutedakis Y; Kitas GD
    Arthritis Res Ther; 2012 Jul; 14(4):R160. PubMed ID: 22765047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
    Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
    BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis.
    Kiortsis DN; Mavridis AK; Vasakos S; Nikas SN; Drosos AA
    Ann Rheum Dis; 2005 May; 64(5):765-6. PubMed ID: 15458960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis.
    Goodman SM; Menon I; Christos PJ; Smethurst R; Bykerk VP
    Rheumatology (Oxford); 2016 Mar; 55(3):573-82. PubMed ID: 26447162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of anti-TNF-α biologics on insulin resistance and insulin sensitivity in patients with rheumatoid arthritis: An update systematic review and meta-analysis.
    Lim WS; Teoh SE; Tang ASP; Tan BJM; Lee JY; Yau CE; Thumboo J; Ng QX
    Diabetes Metab Syndr; 2024 Apr; 18(4):103001. PubMed ID: 38604059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
    Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
    Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor Inhibitor Cycling or Switching to a New Mechanism of Action Therapy: Real-world Observational Study of Rheumatoid Arthritis Patients in the United States with Prior Tumor Necrosis Factor Inhibitor Therapy.
    Wei W; Knapp K; Wang L; Chen CI; Craig GL; Ferguson K; Schwartzman S
    Adv Ther; 2017 Aug; 34(8):1936-1952. PubMed ID: 28674959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry.
    Rotar Z; Hočevar A; Rebolj Kodre A; Praprotnik S; Tomšič M;
    Clin Rheumatol; 2015 Oct; 34(10):1787-93. PubMed ID: 26345633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Year Tuberculosis Risk in Rheumatoid Arthritis Patients Starting Their First Tumor Necrosis Factor Inhibitor Therapy from 2008 to 2012 in Taiwan: A Nationwide Population-Based Cohort Study.
    Lim CH; Lin CH; Chen DY; Chen YM; Chao WC; Liao TL; Chen HH
    PLoS One; 2016; 11(11):e0166339. PubMed ID: 27832150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
    Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
    Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
    Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC
    Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
    J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
    Hernández MV; Sanmartí R; Cañete JD
    Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis.
    Daïen CI; Duny Y; Barnetche T; Daurès JP; Combe B; Morel J
    Ann Rheum Dis; 2012 Jun; 71(6):862-8. PubMed ID: 22267329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.
    Schoels M; Aletaha D; Smolen JS; Wong JB
    Ann Rheum Dis; 2012 Aug; 71(8):1303-8. PubMed ID: 22294630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials.
    Siu S; Haraoui B; Bissonnette R; Bessette L; Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Kraft J; Lynde C; Gulliver W; Keeling S; Dutz J; Pope JE
    Arthritis Care Res (Hoboken); 2015 May; 67(6):754-64. PubMed ID: 25418272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.